Profil
Willem Hazenberg served as a Director-Supervisory Board at Mucosis BV from 2007 to 2009.
He also served as a Director-Supervisory Board at Piculet Biosciences BV and as a Director at NewAmsterdam Pharma BV.
From 2006 to 2017, he was a Partner at Biogeneration Management BV.
He also served as a Member-Supervisory Board at SurgVision BV.
Hazenberg graduated from the University of Groningen and earned a doctorate from the Swiss Federal Institute of Technology.
Anciens postes connus de Willem Hazenberg
| Sociétés | Poste | Fin |
|---|---|---|
Biogeneration Management BV
 Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Private Equity Investor | 31/12/2017 |
SurgVision BV
 SurgVision BV Medical SpecialtiesHealth Technology SurgVision BV provides optical imaging camera systems. It develops integrated optical imaging platforms, including camera, software and target specific tracer, for specific disease areas like breast cancer surgery. The company was founded by Vasilis Ntziachristos and Ton van den Hoven in 2011 and is headquartered in 't Harde, the Netherlands. | Directeur/Membre du Conseil | - |
Piculet Biosciences BV
 Piculet Biosciences BV BiotechnologyHealth Technology Piculet Biosciences BV develops and markets oligonucleotide binding moieties for pharmaceutical applications. The firm’s oligonucleotide synthesis system combines pace derived hardware engineering with biochemistry and nucleotide photo-deprotection technology into an integrated bench-top instrument for oligonucleotide production. The company was founded in December 2004 and is headquartered in Leiden, the Netherlands. | Directeur/Membre du Conseil | - |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Directeur/Membre du Conseil | - |
Mucosis BV
 Mucosis BV Miscellaneous Commercial ServicesCommercial Services Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands. | Président | 07/07/2009 |
Formation de Willem Hazenberg
| University of Groningen | Graduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Finance |
Mucosis BV
Mucosis BV Miscellaneous Commercial ServicesCommercial Services Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands. | Commercial Services |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Health Technology |
Piculet Biosciences BV
Piculet Biosciences BV BiotechnologyHealth Technology Piculet Biosciences BV develops and markets oligonucleotide binding moieties for pharmaceutical applications. The firm’s oligonucleotide synthesis system combines pace derived hardware engineering with biochemistry and nucleotide photo-deprotection technology into an integrated bench-top instrument for oligonucleotide production. The company was founded in December 2004 and is headquartered in Leiden, the Netherlands. | Health Technology |
SurgVision BV
SurgVision BV Medical SpecialtiesHealth Technology SurgVision BV provides optical imaging camera systems. It develops integrated optical imaging platforms, including camera, software and target specific tracer, for specific disease areas like breast cancer surgery. The company was founded by Vasilis Ntziachristos and Ton van den Hoven in 2011 and is headquartered in 't Harde, the Netherlands. | Health Technology |
